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Chagas disease (CD) is endemic to Latin America; its 
prevalence is highest in Bolivia. CD is sometimes seen in 
the United States and Canada among migrants from Latin 
America, whereas it is rare in Europe. We report 9 cases of 
imported CD in France from 2004 to 2006.  
N
ine cases of  Chagas disease (CD), although rare in 
France, have been diagnosed in the country from 
2004 through 2006 (online Appendix Table, available from 
http://www.cdc.gov/EID/content/14/4/644-appT.htm.). 
These included 1 case of acute Chagas myocarditis (ACM), 
4 cases of chronic Chagas cardiomyopathy (CCC), and 4 
cases of indeterminate chronic Chagas (ICC) (asymp-
tomatic patients seropositive for Trypanosoma cruzi) (1). 
The ACM case involved an otherwise healthy 26-year-old 
woman who was hospitalized in September 2004 when she 
returned from a 2-month stay in French Guiana. Her symp-
toms included fever, headache, photophobia, intermit-
tent chest pain, and arthromyalgia. Physical examination 
showed a typical Romaña sign, i.e., unilateral periorbital 
swelling (Figure). No abnormalities were found on clinical 
workup; blood smears and cultures were negative. Results 
of lumbar puncture, chest radiography, and echocardiog-
raphy were also negative. The electrocardiogram (ECG) 
showed anterior ST-segment depression. A smear of a blis-
ter adjacent to the eye showing the Romaña sign yielded T. 
cruzi on direct examination. PCR was not performed. The 
patient was treated orally with benznidazole, 150 mg twice 
a day, and had a good clinical response. Benznidazole was 
discontinued after 7 weeks because peripheral neuropathy 
had developed. T. cruzi serologic results remained negative 
until 4 months after ACM, either because of a lack of sensi-
tivity or because the patient was treated as soon as possible 
at the onset of symptoms.
The median age of the other 8 patients (4 men and 4 
women from Bolivia) with chronic CD was 38 years (24–
48). Seven patients had been living in France for 2 to 5 years. 
One of the patients with ICC was the son of a woman with 
CCC. Symptoms were mainly cardiologic, with atypical 
chest pain, dyspnea (New York Heart Association [NYHA] 
class 3–4), syncope, lipothymia, and fatigue (online Ap-
pendix Table). Two patients were symptom free, including 
1 in whom relatively severe cardiac disease was later diag-
nosed with. Five of these 8 patients had a family history of 
CCC. Clinically, all patients had bradycardia, hepatojugu-
lar reﬂ  ux, or lower limb edema. Four patients had a normal 
clinical examination. No anomalies were found (complete 
blood cell count, transaminases, creatinine phosphokinase, 
troponin, C-reactive protein). The ECGs of all 4 patients 
with CCC showed bradycardia, including sinoatrial block 
(SAB) in 2 patients, and grade III atrioventricular block 
(AVB) in 2 patients. One patient had a right bundle branch 
block and a left anterior semiblock. Chest radiographs were 
normal. Transthoracic echocardiography showed a severe 
reduction in the left ventricular ejection fraction (20%) in 
1 patient. Holter ECG conﬁ  rmed the conduction abnor-
malities in 3 of the 4 patients (SAB, AVB, and ventricular 
hyperexcitability in 2 patients). All 8 patients had a posi-
tive indirect immunoﬂ  uorescence test (IIF) and a positive 
ELISA test (2) for T. cruzi in serum (online Appendix 
Table). The 8 patients were IIF-negative for Leishmania 
(3). The 2 patients with AVB III had pacemakers implanted 
and received angiotensin-converting-enzyme inhibitor and 
β-blocker therapy. Eight patients received oral benznida-
zole, 5 mg/kg/day for 1 to 8 weeks, depending on toler-
ability. Antihistamine therapy was given throughout ben-
znidazole administration. One patient developed DRESS 
syndrome (drug rash with eosinophilia and systemic symp-
toms) after 2 weeks of treatment and improved a few days 
after benznidazole interruption. Nifurtimox was given (and 
was well tolerated) after the patient’s cutaneous and blood 
status had normalized. Three patients complained of numb-
ness of the extremities during weeks 4, 5, and 7 of treat-
ment; this pointed to benznidazole-induced peripheral neu-
ropathies, which effectively disappeared when treatment 
was stopped. Three patients stopped taking their treatment 
prematurely; 1 patient was switched to nifurtimox after 2 
weeks of treatment with benznidazole. Two patients report-
ed a lessening of pain and improvements in their general 
health after antiparasitic treatment.
The prevalence of CD in T. cruzi–exposed, asymptom-
atic persons living in Europe is about 0.6% to 4% (4,5). Al-
though CD remains extremely rare in Europe, a review of 
the literature shows 5 symptomatic cases up to 2004. There 
was 1 case of imported ACM in France in 1988 in a patient 
from Colombia (6), 1 case of autochthonous ACM in Spain 
in 1992 after blood transfusion (7), 1 case of imported CCC 
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in Switzerland in 1996 in a patient from Bolivia (8), 1 case 
of imported ACM in Italy in 1997 in a patient from Brazil 
(9), and 1 case of imported ICC in Denmark in 2000 in a 
patient from Venezuela (10). After 2004, 3 additional  cases 
were reported: 2 cases in Spain in 2005 (1 case of imported 
CCC in a patient from Bolivia)  (11), 1 case of autochtho-
nous neonatal ACM in the child of a Bolivian mother (12), 
and 1 case of imported CCC in the Netherlands in 2006 in a 
patient from South America (country not speciﬁ  ed) (13).
Acute forms of CD diagnosed in Europe usually in-
volve Europeans returning from stays in disease-endemic 
areas. The acute case described here underlines, as previ-
ously stated by Brisseau et al. (6), that a short stay in a 
disease-endemic zone, even for a few days, is sufﬁ  cient 
to become a potential source of T. cruzi. In France, since 
April 2007, all persons who have spent any time in Central 
or South America are screened for T. cruzi before blood 
donation. This recent measure followed a series of 4 acute 
Chagas cases in French Guiana (14). Chronic imported 
forms usually involve South American immigrants, whose 
numbers are difﬁ  cult to determine in Europe as many are 
illegal. The number of persons of Latin American origin 
living in metropolitan France has risen from 27,400 in 1999 
to 105,000 in 2005 according to the National Institute for 
Demographic Studies (www.ined.fr). These persons are an 
underestimated potential source of transmission of disease. 
As illustrated by the cases recently reported by C. Riera 
(12), there is also a risk of transplacental transmission in 
women of South American origin living in Europe. CCC is 
sometimes life threatening, as in the case of patient 4 (on-
line Appendix Table), who had a very poor cardiac progno-
sis for a 38-year-old man.
The diagnosis of CD is not always straightforward in 
France. The current rarity of CD in Europe and the purely 
cardiologic (and sometimes gastrointestinal) manifesta-
tions of the chronic phase represent a diagnostic challenge. 
In France, few cardiologists and gastroenterologists are 
fully aware of this infectious disease. In the United States, 
because imported cases of CD are no longer exceptional, a 
Chagas screening test for blood donors was implemented in 
2007 (15). The 9 cases we report, along with other recent 
cases, may be a sign that CD is emerging in France. If this 
imported disease becomes established in France, it could 
represent a real risk for transfusional and congenital trans-
mission, not only in metropolitan areas in France but also 
in other European countries with a high Latin American 
immigrant population. 
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